Safety board clears TxCell to restart Ovasave study that was halted last year

By Gareth Macdonald contact

- Last updated on GMT

TxCell has been cleared to restart a Phase IIb trial of its candidate Crohn’s disease cell therapy by European regulators.

The study – named CATS29​ – stopped last year​ after regulator ANSM (Agence nationale de sécurité du medicament) raised concerns about the potential risk of microbial contamination at a manufacturing facility in Besancon where Ovasave was being produced.

Since then TxCell has hired contract manufacturers - Caladrius Biosciences’ subsidiary PCT in the US and MaSTherCell in Belgium – and amended the trial protocol.

In addition, the data and safety monitoring board (DSMB) overseeing CATS29 conducted a review of all available data from previously treated patients.

A spokeswoman for TxCell told us approval to restart study was granted by European authorities through the Voluntary Harmonisation Procedure (VHP) based on the DSMB's recommendations.

She added that: "The DSMB is made up of four independent experts in the field, using unblinded data​."

TxCell plans to resume CATs29 as soon as possible and expects top-line data within 21 months of the restart.


The news follows just a few months after TxCell regained full rights to Ovasave from cell therapy development firm Trizell.

Trizell had been working on Ovasave – including running the CATS29 study - since January 2014 when TxCell and partner Ferring Pharmaceuticals handed over development rights.

However, last December TxCell paid Trizell €15m ($15.9m) to regain full rights to the product. At the time TxCell outlined how it would modify the trial protocol.

The firm said while it would retain the primary endpoint of a Crohn's disease activity index (CDAI) response to a 1 million cell dose of the product vs placebo it would omit the dose-ranging arms of the trial.

Related news

Show more

Related products

show more

Protect your bulk filtration and dispense step

Protect your bulk filtration and dispense step

Parker Bioscience Filtration | 22-Jul-2019 | Data Sheet

Does your process need greater protection when the value of your product is at its highest?

At the bulk filtration and container fill stage,...

rAAV Production in BioBLU® Single-Use Vessels

rAAV Production in BioBLU® Single-Use Vessels

Eppendorf for Bioprocess – Solutions that grow with you | 25-Jun-2019 | Application Note

Rising interest in gene therapy-based applications leads to increasing demands in scalable production systems for viral vectors. Find out how Cevec Pharmaceuticals...

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Related suppliers

Follow us


View more